Organization & Developments: Crescendo

Parents

Molecular diagnostic test for patients with rheumatoid arthritis.
Provides quantitative, objective molecular tests to provide rheumatologists with deeper clinical insights into biology, to help enable more effective management of patients with autoimmune and inflammatory diseases.
The treatments cost upwards of $20,000 a year per patient, they don’t work for everybody, and even for those who do get relief, results can vary.
This test, introduced to the U.S. market in November 2010, looks at 12 different biomarkers in a blood sample to provide a quantitative measurement of the activity of inflammation at work in a patient with rheumatoid arthritis
Three of the world’s top six best-selling drugs in 2010 were biotech medicines for this condition, and related autoimmune disorders.